Health Trials

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

ConditionsLymphoma, Non-HodgkinMultiple MyelomaAdvanced Solid Tumors
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age12+
SponsorAmerican Society of Clinical Oncology

About this trial

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug.

NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact [email protected], or if a patient, your nearest participating TAPUR site (see participating centers).

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress.

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

Eligibility criteria

Qualifiers

12 years of age or older (*Restrictions apply. Not all therapies are available for patients <18)

Histologically-proven locally advanced or metastatic solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma who is no longer benefiting from standard anti-cancer treatment or for whom, in the opinion of the treating physician, no such treatment is available or indicated

Performance status 0-2 (Per Eastern Cooperative Oncology Group (ECOG) criteria)

Patients must have acceptable organ function as defined below. However, as noted above, drug-specific inclusion/

Disqualifiers

Absolute neutrophil count ≥ 1.5 x 106/µl

Hemoglobin > 9.0 g/dl

Platelets > 75,000/µl

Total bilirubin < 2.0 mg/ dl, except in patients with Gilbert's Syndrome

Trial design

Treatments tested in this trial

  • Palbociclib
  • Sunitinib
  • Temsirolimus
  • Trastuzumab and Pertuzumab
  • Vemurafenib and Cobimetinib
  • Regorafenib
  • Olaparib
  • Nivolumab and Ipilimumab
  • Abemaciclib
  • Talazoparib
  • Atezolizumab and Talazoparib
  • Tucatinib plus Trastuzumab Subcutaneous (SC)
  • Futibatinib
  • Dabrafenib plus Trametinib
  • Fam-Trastuzumab Deruxtecan-Nxki (TDxD)

Treatment groups

4,200 Participants
are divided into 15 treatment groups

15

Treatment groups

See each treatment group below.

Sponsors and collaborators

American Society of Clinical Oncology

Lead sponsor

AstraZeneca

Collaborator

Bayer

Collaborator

Bristol-Myers Squibb

Collaborator

Eli Lilly and Company

Collaborator

Genentech, Inc.

Collaborator

Pfizer

Collaborator

Taiho Oncology, Inc.

Collaborator

Novartis

Collaborator

Merck Institute for Therapeutic Research

Collaborator

Boehringer Ingelheim

Collaborator

Seattle Genetics (now a wholly owned subsidiary of Pfizer)

Collaborator

Source ClinicalTrials.gov